Genetic Testing in Prostate Cancer: Considerations for Urologists and Their Patients Webinar (2020)
Complimentary CME Webinar!
Thursday August 20, 2020 | 2:30 - 3:30 p.m. EDT
Over the last several years, there has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer. Urologists are suddenly being confronted with new information surrounding screening guidelines for men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations.
To increase urologists understanding related to the newest treatment options for prostate cancer, the featured 60-minute panel discussion led by experts in their field, will explore how to translate the latest scientific advances into routine clinical practice, improving the care of patients who are at a markedly-elevated risk of progressions and death from prostate cancer.
The Genetic Testing in Prostate Cancer: Considerations for Urologists and their Patients Webinar will be recorded and available in webcast format on AUAUniversity and AUA’s YouTube channel. Additionally, the content will be released as an episode on AUA’s podcast. Learners will also be provided with links to access a patient and caregiver video and fact sheet produced by the Urology Care Foundation to increase patient understanding of genetic testing as it relates to prostate cancer, and facilitate enhanced patient – physician communications in regards to treatment options.
Acknowledgements
This educational series is supported by an independent educational grant from:
- AstraZeneca
- Merck
- Pfizer Inc.
Target Audience
- Urologists
Learning Objectives
At the conclusion of the activity, participants will be able to:
- State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
- Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.
- Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.
- Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.
Times are listed in EDT and are subject to change.
Thursday, August 20, 2020 | |
---|---|
2:30–2:40 p.m. | Welcome/Introduction & Pre-Test |
Session I | |
2:40–2:50 p.m. | Background: Increased Understanding of the Role of Genetic Testing Over the Past Several Years |
2:50–3:00 p.m. | Testing Criteria & Options |
Session III | |
3:00–3:10 p.m. | Genetic Testing Results & Patient Communication |
Session IV | |
3:10–3:25 p.m. | Testing for Germline Mutations & Novel Therapies |
3:25–3:30 p.m. | Post-Test |
3:30 p.m. | Course Adjourns |
Genetic Testing in Prostate Cancer: Considerations for Urologists and Their Patients Webinar (2020) will be held virtually on Thursday, August 20, 2020 at 2:30 PM EST.
***Instructions***
- Click the "Register" tab.
- If prompted, click “update your profile”. Otherwise, click “Take Course”.
- Click “Start” under Live Webinar in the Course Progress pane.
- Click "Join Webinar".
Education Council Disclosures
Education Council & COI Reviewer Disclosure_082020.pdf
AUA Office of Education Staff has nothing to disclose.
Faculty disclosures will be posted here prior to the start of the course.
Todd Morgan, MD
Matthew Cooperberg, MD
Veda Giri, MD
Daniel Lin, MD
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA Participant Information and Policies
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:
The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
SPECIAL ASSISTANCE/DIETARY NEEDS:
The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation